It is bio-tech play. Catalyst is beyond my understanding, market chart looks good and EP day volume is almost 3x of its float (8.3M). the company announced it found its lead drug to be safe in a cardiac safety study.
The company is evaluating the drug pyridorin in a late-stage trial in patients with diabetic nephropathy, a chronic and degenerative kidney disease caused by diabetes and often tied to heart disease.
NephroGenex said it has noted cardiac safety concerns with other therapies currently in development.
没有评论:
发表评论